WuXi Biologics is giving CDMO Terumo the keys to its site in Leverkusen, Germany, with a 150 million euros ($167 million) sale. With the deal, WuXi Biologics can “exclusively focus” on ...

Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development ...

To address the challenges in producing these biomolecules, WuXi Biologics has introduced the EffiX™ platform, which enables the development and manufacturing of microbial-derived biologics with ...

In the newly published ratings scorecard, WuXi Biologics was ranked in the top 1% of more than 150,000 companies evaluated worldwide. Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG ...

WuXi 2269-3.02%decrease; red down pointing triangle Biologics agreed to sell an overseas vaccine facility to Merck MRK-3.31%decrease; red down pointing triangle & Co. for half a billion dollars ...

WUXI and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced ...

The market's opinion of WuXi Biologics' 2024 financial prospects is negative, taking into account elevated interest rates and geopolitical risk factors. Recent share repurchases support the view ...

Following a similarly optimistic forecast from WuXi AppTec—and amid a national security-related controversy in the U.S.—Chinese contract developer and manufacturer WuXi Biologics is ...

WuXi Biologics shares have fallen 30% since the Biosecure Act bill was proposed in the U.S. House of Representatives, which seeks to ban the use of U.S. genomics by Chinese companies. While we don ...

Wuxi Biologics has said that its operations remain normal and that it expects revenue to expand about 10% this year, coming after shares of the Chinese contract drugmaker slid 24% and were halted ...

WuXi Biologics Plunges 24% as Covid Boost, Biotech Boom Fade Bourse suspends stock trading pending release of announcement Industry ‘faces near-term challenges’ on slow growth: WuXi Bio ...

the contract medical researching unit of WuXi Biologics (Cayman) (2269.HK), opens new tab, said on Tuesday it intended to raise up to HK$3.68 billion ($470.56 million) in one of Hong Kong's top ...